Diltiazem XR Shortage Update: What Patients Need to Know in 2026

If you've been having trouble filling your Diltiazem XR prescription in 2026, you have plenty of company. Patients across the country have been reporting that their regular pharmacy is out of stock, out of their specific strength, or stocking only a different formulation type they can't use without a new prescription. Here's the honest 2026 update on what's happening and what you can do.

Is Diltiazem XR Officially in Shortage in 2026?

As of early 2026, oral Diltiazem extended-release products — including the various XR, CD, LA, and XT formulations — are not listed on the FDA's official Drug Shortage Database. This means there is no declared national shortage of the oral forms.

The injectable form of diltiazem (used in hospitals for IV rate control) is a different story. That shortage has been listed by the FDA and tracked by ASHP since June 2015 — over a decade of ongoing supply problems for the IV form. If you take oral Diltiazem XR, this IV shortage doesn't directly affect your prescription.

So Why Can't I Find My Diltiazem XR?

"No official shortage" doesn't mean your pharmacy has it. Patients are experiencing real, practical shortages at the pharmacy level — just not the kind the FDA formally tracks. The reasons are structural:

Formulation fragmentation. Diltiazem XR comes in many formulation types (Cardizem CD, Cardizem LA, Tiazac, Cartia XT, Dilacor XR, Matzim LA) that each release the drug differently and are not AB-rated as interchangeable. A shortage of one type doesn't get offset by stock of another.

Thin generic margins. Generic diltiazem ER is inexpensive, which is good for patients but creates fragile supply chains. Manufacturers maintain minimal inventory buffers.

Higher-strength stockouts. Doses like 300 mg, 360 mg, and 420 mg are less commonly stocked at smaller pharmacies. Even certain popular strengths like 120 mg and 360 mg have seen regional gaps.

Insurance formulary friction. Some insurance plans prefer specific formulation generics, which concentrates demand at certain pharmacies and can deplete their stock faster.

Diltiazem XR Shortage Timeline: How We Got Here

The history of diltiazem supply issues helps explain the current situation:

June 2015: FDA first reports a shortage of diltiazem hydrochloride injection. Multiple manufacturers experience supply disruptions.

2015–2021: Intermittent availability from multiple manufacturers. ASHP consistently lists diltiazem injection as a current shortage.

Mid-2022: Akorn Operating Company ceases all operations and discontinues its diltiazem injection products, removing one of three suppliers from the market.

2019 onward: Oral diltiazem ER begins experiencing intermittent supply disruptions at the pharmacy level, though no formal FDA shortage declaration is made.

2026: Injectable diltiazem shortage continues. Oral ER products are generally available nationally but with localized gaps, especially for certain strengths and formulation types.

What Should Patients Do Right Now?

Don't panic — but do act proactively. Here's your action plan:

Search for pharmacies with your medication in stock using medfinder.

Refill early — try to always maintain at least a 7–10 day buffer of medication.

Call your doctor if you cannot find your medication within 2–3 days. Ask about a formulation switch or a temporary bridge medication.

Consider switching to a 90-day mail-order supply to reduce the frequency you need to refill.

Never abruptly stop taking Diltiazem XR — this can cause dangerous rebound hypertension or angina.

What Is the Outlook for Diltiazem XR Availability in 2026?

For oral diltiazem XR, the outlook is cautiously optimistic. Multiple generic manufacturers — including Teva, Mylan (Viatris), Lupin, and Aurobindo — produce various diltiazem ER formulations. The drug is off-patent and widely manufactured. The main challenges are structural (formulation fragmentation, thin margins) rather than production-related.

For injectable diltiazem, the situation is more challenging. With only two to three active manufacturers and no new market entrants announced, the hospital-use IV form is likely to remain on allocation through 2026 and beyond.

If your pharmacy is consistently out of stock, learn about your options in Alternatives to Diltiazem XR If You Can't Fill Your Prescription.